BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 28961375)

  • 1. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.
    Lücking U; Scholz A; Lienau P; Siemeister G; Kosemund D; Bohlmann R; Briem H; Terebesi I; Meyer K; Prelle K; Denner K; Bömer U; Schäfer M; Eis K; Valencia R; Ince S; von Nussbaum F; Mumberg D; Ziegelbauer K; Klebl B; Choidas A; Nussbaumer P; Baumann M; Schultz-Fademrecht C; Rühter G; Eickhoff J; Brands M
    ChemMedChem; 2017 Nov; 12(21):1776-1793. PubMed ID: 28961375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
    Lücking U; Kosemund D; Böhnke N; Lienau P; Siemeister G; Denner K; Bohlmann R; Briem H; Terebesi I; Bömer U; Schäfer M; Ince S; Mumberg D; Scholz A; Izumi R; Hwang S; von Nussbaum F
    J Med Chem; 2021 Aug; 64(15):11651-11674. PubMed ID: 34264057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.
    Wang B; Wu J; Wu Y; Chen C; Zou F; Wang A; Wu H; Hu Z; Jiang Z; Liu Q; Wang W; Zhang Y; Liu F; Zhao M; Hu J; Huang T; Ge J; Wang L; Ren T; Wang Y; Liu J; Liu Q
    Eur J Med Chem; 2018 Oct; 158():896-916. PubMed ID: 30253346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.
    Barlaam B; Casella R; Cidado J; Cook C; De Savi C; Dishington A; Donald CS; Drew L; Ferguson AD; Ferguson D; Glossop S; Grebe T; Gu C; Hande S; Hawkins J; Hird AW; Holmes J; Horstick J; Jiang Y; Lamb ML; McGuire TM; Moore JE; O'Connell N; Pike A; Pike KG; Proia T; Roberts B; San Martin M; Sarkar U; Shao W; Stead D; Sumner N; Thakur K; Vasbinder MM; Varnes JG; Wang J; Wang L; Wu D; Wu L; Yang B; Yao T
    J Med Chem; 2020 Dec; 63(24):15564-15590. PubMed ID: 33306391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death.
    Ruff JP; Kretz AL; Kornmann M; Henne-Bruns D; Lemke J; Traub B
    Anticancer Res; 2021 Dec; 41(12):5973-5985. PubMed ID: 34848451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.
    Rahaman MH; Yu Y; Zhong L; Adams J; Lam F; Li P; Noll B; Milne R; Peng J; Wang S
    Invest New Drugs; 2019 Aug; 37(4):625-635. PubMed ID: 30194564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models.
    Wang L; Hu C; Wang A; Chen C; Wu J; Jiang Z; Zou F; Yu K; Wu H; Liu J; Wang W; Wang Z; Wang B; Qi Z; Liu Q; Wang W; Li L; Ge J; Liu J; Liu Q
    Invest New Drugs; 2020 Oct; 38(5):1272-1281. PubMed ID: 31872348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.
    Sonawane YA; Taylor MA; Napoleon JV; Rana S; Contreras JI; Natarajan A
    J Med Chem; 2016 Oct; 59(19):8667-8684. PubMed ID: 27171036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia.
    Han X; Song N; Saidahmatov A; Wang P; Wang Y; Hu X; Kan W; Zhu W; Gao L; Zeng M; Wang Y; Li C; Li J; Liu H; Zhou Y; Wang J
    J Med Chem; 2021 Oct; 64(19):14647-14663. PubMed ID: 34477384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9.
    Phillipson LJ; Segal DH; Nero TL; Parker MW; Wan SS; de Silva M; Guthridge MA; Wei AH; Burns CJ
    Bioorg Med Chem; 2015 Oct; 23(19):6280-96. PubMed ID: 26349627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.
    Barlaam B; De Savi C; Dishington A; Drew L; Ferguson AD; Ferguson D; Gu C; Hande S; Hassall L; Hawkins J; Hird AW; Holmes J; Lamb ML; Lister AS; McGuire TM; Moore JE; O'Connell N; Patel A; Pike KG; Sarkar U; Shao W; Stead D; Varnes JG; Vasbinder MM; Wang L; Wu L; Xue L; Yang B; Yao T
    J Med Chem; 2021 Oct; 64(20):15189-15213. PubMed ID: 34647738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
    Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
    Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK9 inhibitors in acute myeloid leukemia.
    Boffo S; Damato A; Alfano L; Giordano A
    J Exp Clin Cancer Res; 2018 Feb; 37(1):36. PubMed ID: 29471852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.
    Li Y; Guo Q; Zhang C; Huang Z; Wang T; Wang X; Wang X; Xu G; Liu Y; Yang S; Fan Y; Xiang R
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3231-3237. PubMed ID: 28651979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
    Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Halogen bonds form the basis for selective P-TEFb inhibition by DRB.
    Baumli S; Endicott JA; Johnson LN
    Chem Biol; 2010 Sep; 17(9):931-6. PubMed ID: 20851342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
    Wang X; Yu C; Wang C; Ma Y; Wang T; Li Y; Huang Z; Zhou M; Sun P; Zheng J; Yang S; Fan Y; Xiang R
    Eur J Med Chem; 2019 Nov; 181():111535. PubMed ID: 31376566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.
    Li MC; Lin WH; Wang PC; Su YC; Chen PY; Fan CM; Chen CP; Huang CL; Chiu CH; Chang L; Chen CT; Yeh TK; Hsieh HP
    Eur J Med Chem; 2021 Nov; 224():113673. PubMed ID: 34303872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells.
    Štětková M; Growková K; Fojtík P; Valčíková B; Palušová V; Verlande A; Jorda R; Kryštof V; Hejret V; Alexiou P; Rotrekl V; Uldrijan S
    Cell Death Dis; 2020 Sep; 11(9):754. PubMed ID: 32934219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
    Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
    Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.